An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
Conditions: Non-Metastatic Prostate Carcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; S tage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8 Intervention: Radiation: 7 Tesla Magnetic Resonance Imaging Sponsors: University of Southern California; National Cancer Institute (NCI) Not yet recruiting
This study investigated the performance of 68Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with 68Ga-prostate-specific-membrane-antigen-11 were evaluated retrospectively. Prostate-specific-antigen-stratified cohorts of pathological scan results were analyzed, and relationships between prostate-specific-antigen kinetics and PSMA-positive tumor lesions were...
Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.
186Introduction: Patients with prostate cancer can be stratified into high and low risk on the basis of prostate specific antigen (PSA) levels, Gleason score at biopsy and clinical stage. High risk PCa needs skeletal evaluation for detection of distant metastasis, widely used method being bone scan. Limitations of the bone scan has brought 18F- FluoridePET/CT to the forefront which is highly sensitive. PET/CT with Ga68-labeled PSMA inhibitor has been shown to be of high clinical value for lymph node staging and is emerging as the imaging modality of choice for PCa staging. Aim: The purpose of this study was to compare the ...
Conclusions: 68Ga PSMA-11 PET/MR is overall highly concordant with surgical pathology and provides complementary information to multiparametric MR for assessment of extent of cancer involvement in prostate gland and pelvic nodes. Patients without nodal involvement on PET in our cohort had a low probability of biochemical recurrence in two years after imaging.
Conclusions: Limited [18F] NaF PET/CT (VMT) study acquisition is almost sufficient for diagnosis of most of neoplastic disease assessment providing less study time and lower CT-Scan absorbed dose. Reference: Ahuja, K., Sotoudeh, H., Galgano, S. J., Singh, R., Gupta, N., Gaddamanugu, S., &Choudhary, G. (2019). 18F-Sodium fluoride positron emission tomography: History, technical feasibility, mechanism of action, normal bio-distribution, and diagnostic performance in bone metastasis detection compared to other imaging modalities. Journal of Nuclear Medicine Technology, jnmt.119.234336.
Conclusions: This study demonstrates that the tumor uptake and biodistribution of [89Zr]-PSMA Df in normal tissues is comparable to that of [68Ga]-PSMA 11 and [18F]-JK-PSMA 7, but remains in the tumor for at least 52 h p.i. with increasing tumor-to-background ratio. This, together with the long half-life of the [89Zr]-label allows late PET-acquisition with improved lesion detection. Tumors with lower PSMA expression are thus more likely to be detected than with existing 18F- or 68Ga labeled PSMA targeted imaging agents.
Conclusion: PET/CT has proven to be an effective tool in guiding the use of specific targets for drug delivery to spontaneously occurring disease. The result of this work validates results shown in previous mice studies. Comparative oncology enables researches to further understand the mechanisms of human disease and fast-track drug development. The utility of HBP as a transport mechanism for chemotherapy drugs using PET/CT to determine personalised targets is currently being investigated in canine models.
Conclusions: KS1 do not generate ROS in tumor cells at tracer level concentrations (≤100 uM) and tumor-killing properties by inducing ROS generation at pharmacologic doses (≥1.0 mM), and behave like ascorbate. [18F]KS1 exhibited high tumor uptake in vivo, with superior specificity and selectivity, and favorable pharmacokinetics in several tumor-bearing mice. This would be the first [18F]-based PET tracer, based on a natural vitamin to image ROS in tumor cells in vivo, with a clear mechanistic profile. Based on our promising data, we hypothesize that ascorbate-based PET ligand strategy will expand the ascorbate scaffo...
Conclusion: The new compound BPD appears to be interesting tracer for use in the targeted radionuclide treatment of PC with AR overexpression and provides a good alternative to conventional PSMA ligands. It can be used in diagnosis as [68Ga]BPD as well as in therapy as [177Lu]BPD.
A 51-year-old man with 30-year neurofibromatosis and 2-month elevated prostate-specific antigen and back pain underwent a 68Ga–prostate-specific membrane antigen (PSMA) PET/CT scan for possible prostate cancer. Prostate-specific membrane antigen PET/CT imaging showed no abnormal uptake of the prostate. However, in addition to PSMA uptake in his left lung, thorax, and right ilium, which was confirmed being a lung squamous cell carcinoma by a lung biopsy, widespread uptake was also observed in his skin fibroma lesions. This case demonstrates that benign neurofibromatosis could have uptake of PSMA.